Study of Azacitidine and Durvalumab in Advanced Solid Tumors
Status:
Completed
Trial end date:
2020-08-04
Target enrollment:
Participant gender:
Summary
This is a phase 2 study of investigational drug, durvalumab given in combination with
azacitidine (CC-486). The main purpose of this phase 2 study is to assess the antitumor
activity of azacitidine in combination with durvalumab patients with microsatellite stable
colorectal carcinoma (MSS-CRC), platinum resistant epithelial ovarian cancer type II (PR-OC),
and estrogen receptor positive and HER2 negative breast cancer.